BEMA Buprenorphine meets endpoints in Phase III Pain study-Endo Pharma/BioDelivery Sci
Endo Pharmaceuticals and BioDelivery Sciences International announced positive top-line results from its pivotal Phase III efficacy study of BEMA Buprenorphine (buprenorphine/naloxone) in the treatment of chronic lower back Pain in opioid-experienced patients. The trial successfully met its primary efficacy endpoint in demonstrating that BEMA buprenorphine resulted in significantly improved chronic Pain relief compared to placebo.
Additional secondary endpoints were supportive of the efficacy of BEMA buprenorphine compared to placebo. The most commonly reported adverse events in patients treated with buprenorphine compared to placebo were nausea (7.5% vs. 7.4%) and vomiting (5.5% vs. 2.3%).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins